Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 74Breast 22Gastrointestinal 17Head & Neck 16Genitourinary 14CNS 9Sarcoma 6Gynecologic 5Tumor-Agnostic 3Other solid neoplasm 3Endocrine 3Dermatologic 2Other hematologic neoplasm 1

Conditions

Vipoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Gefitinib × Endocrine × Clear all
NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
16 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Massachusetts General Hospital

Phase 2 Completed
27 enrolled 16 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00075439 2013-06-04

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
90 enrolled
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡